Who are Macitentan Tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): macitentan (ACT-064992), Macitentan Group, Tryvio, SPARSENTAN, Opsumit, Letairis.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/macitentan-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Macitentan Tablets — Competitive Intelligence Brief

Macitentan Tablets (Macitentan Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Endothelin receptor antagonist. Area: Cardiovascular.

phase 3 Endothelin receptor antagonist ETA and ETB receptors Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Macitentan Tablets (Macitentan Tablets) — Dr Sudarshan Rajagopal. Macitentan is a dual endothelin receptor antagonist that blocks both ETA and ETB receptors to reduce pulmonary vascular resistance and improve exercise capacity in pulmonary arterial hypertension.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Macitentan Tablets TARGET	Macitentan Tablets	Dr Sudarshan Rajagopal	phase 3	Endothelin receptor antagonist	ETA and ETB receptors
macitentan (ACT-064992)	macitentan (ACT-064992)	Actelion	phase 3	Endothelin receptor antagonist	ETA and ETB receptors
Macitentan Group	Macitentan Group	University of Giessen	phase 3	Dual endothelin receptor antagonist	ETA and ETB receptors
Tryvio	APROCITENTAN	Idorsia	marketed	Endothelin Receptor Antagonist [EPC]		2025-01-01
SPARSENTAN	SPARSENTAN		marketed	Endothelin Receptor Antagonist [EPC]		2023-01-01
Opsumit	MACITENTAN	AstraZeneca	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2013-01-01
Letairis	AMBRISENTAN	Gilead Sciences	marketed	Endothelin Receptor Antagonist [EPC]	Endothelin-1 receptor	2007-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Endothelin receptor antagonist class)

AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Actelion · 2 drugs in this class
Bayer · 1 drug in this class
Dr Sudarshan Rajagopal · 1 drug in this class
Eli Lilly and Company · 1 drug in this class
Elpen Pharmaceutical Co. Inc. · 1 drug in this class
National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Macitentan Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/macitentan-tablets. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab